Clinical study of besetifan in the treatment of renal cancer: efficacy and research results

Belzutifan (Belzutifan) is a new oral small molecule drug that is a hypoxia-inducible factor-2α (HIF-2α) inhibitor and is specially used to treat patients with HIF-2α An>VHL (von Hippel-Lindau syndrome)-related solid tumors, especially in renal cell carcinoma (RCC), has attracted widespread attention. Unlike traditional targeted therapies, which mainly act on angiogenesis or immune pathways, bezutivan interferes with tumor metabolism and growth pathways from the source by blocking the ability of tumor cells to adapt to a hypoxic environment, representing a new direction in the treatment of kidney cancer.

In multiple pivotal clinical trials, besotivan has shown significant efficacy in the treatment of VHL related clear cell renal cell carcinoma (ccRCC). For example, in a study called LITESPARK-004, which looked at patients with VHL-related kidney cancer who had not undergone surgery, the objective response rate of bezotivan (ORR) reached 49%, and the tumors of some patients completely regressed, and the disease control rate was as high as 90% or more, showing good clinical benefit and tolerability. This provides an important non-invasive treatment option for some patients who are not candidates for surgery or who wish to delay surgery.

In addition to its application in patients with VHL syndrome, bezutivan is also actively explored for the treatment of sporadic renal cancer. In follow-up studies such as LITESPARK-005, besetifan is used in combination with other drugs such as immune checkpoint inhibitors. Preliminary data show that it can further improve the treatment response rate and delay disease progression. This type of combination program is expanding its indications and is expected to provide precise treatment paths for more kidney cancer patients.

In summary, bestivan has shown excellent early efficacy and good safety in the treatment of renal cancer, and is especially suitable for patients with VHL related renal cell carcinoma. With the conduct of more large-scale phase III clinical trials and the accumulation of data, bezutivan is expected to be further expanded to a wider range of kidney cancer subtypes, and may complement existing immunotherapy and targeted programs, bringing new long-term survival hope to kidney cancer patients.

Reference materials:https://www.welireg.com/